Medical Condition News

RSS

Research opens door to new direction of PAH treatment

The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

With low survival rates for patients with metastasized melanoma, accurate staging and effective treatments are critical to extending life. New research published in the Journal of Nuclear Medicine highlights the potential of newly developed radiopharmaceuticals with benzamide for the imaging of metastases and as a targeted systemic therapy.

8 Jan 2014

Cancer statistics 2014 finds steady declines in death rates

The annual cancer statistics report from the American Cancer Society finds steady declines in cancer death rates for the past two decades add up to a 20 percent drop in the overall risk of dying from cancer over that time period.

8 Jan 2014

Notre Dame, Loyola partner to provide direct support for revolutionary new cancer research

Two research powerhouses, Loyola University Chicago and the University of Notre Dame, are joining forces in a multidisciplinary cancer research collaboration.

8 Jan 2014

AP-1 proteins modulate fat accumulation in liver, say researchers

Excessive alcohol consumption, as well as obesity leads to the accumulation of fat in the liver, a disease termed fatty liver disease (FLD) or steatosis. FLD is one of the most prevalent diseases in Western societies and affects about 30% of the adult population. Importantly, FLD increases the risk of liver failure, diabetes and cancer and no pharmacological therapies exist for this detrimental disease.

8 Jan 2014

Research reveals two new genetic causes of neonatal diabetes

Research by the University of Exeter Medical School has revealed two new genetic causes of neonatal diabetes.

8 Jan 2014

Lower bone strength may predispose children to factures resulting from weakened later in life

Broken bones may seem like a normal part of an active childhood. About 1 in 3 otherwise healthy children suffers a bone fracture. Breakage of the bone running from the elbow to the thumb side of the wrist (distal forearm fracture) is the most common.

8 Jan 2014

Study shows ability to make living human cells from biobanked brain tissue of Alzheimer's patients

Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute, working in collaboration with scientists from Columbia University Medical Center (CUMC), for the first time generated induced pluripotent stem (iPS) cells lines from non-cryoprotected brain tissue of patients with Alzheimer's disease.

7 Jan 2014

Added benefit of dabrafenib not proven

Dabrafenib has been approved in Germany since August 2013 for the treatment of advanced melanoma. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the appropriate comparator therapy.

7 Jan 2014

Landes Bioscience releases special issue on sepsis

A special issue on sepsis has been released by the publisher Landes Bioscience (Austin, TX USA). The articles contained in this special issue of the journal Virulence have been authored by world-class investigators and provide new insights into both the pathogen-related factors and the host defense mechanisms that lead to septic shock and contribute to its resolution or fatal outcome.

7 Jan 2014

Erythropoietin may promote cancer cell proliferation and survival

In recent years, non-hematopoietic effects of erythropoietin (EPO), via its binding to the EPO receptor in non-hematopoietic tissues, including cancerous tissues, has been reported by many different laboratories worldwide.

7 Jan 2014

Study sheds light on the biological underpinnings of obesity

A new neuroscience study sheds light on the biological underpinnings of obesity. The in vivo study, published in the January 8 issue of the Journal of Neuroscience, reveals how a protein in the brain helps regulate food intake and body weight. The findings reveal a potential new avenue for the treatment of obesity and may help explain why medications that are prescribed for epilepsy and other conditions that interfere with this protein, such as gabapentin and pregabalin, can cause weight gain.

7 Jan 2014

Applied BioCode signs License and Supply Agreement with Genetic Analysis for BMB technology

Applied BioCode announced today that it has signed a License and Supply Agreement for its Barcoded Magnetic Bead technology with Genetic Analysis of Oslo, Norway.

7 Jan 2014

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency.

7 Jan 2014

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration has accepted and filed for review the company's Biologics License Application for Natpara (recombinant human parathyroid hormone 1-84, (rhPTH[1-84])) for the treatment of hypoparathyroidism.

7 Jan 2014

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the treatment of neuroblastoma in children.

7 Jan 2014

Elderly people with high serum vitamin E levels less likely to suffer from memory disorders

Elderly people with high serum vitamin E levels are less likely to suffer from memory disorders than their peers with lower levels, according to a study published recently in Experimental Gerontology.

7 Jan 2014

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today it has entered into a distribution agreement for Lymphoseek (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd., a leading in-country distributor of nuclear medicine and diagnostic imaging products.

7 Jan 2014

LabStyle Innovations files 510(k) with FDA for Dario Blood Glucose Monitoring System

LabStyle Innovations Corp., developer of Dario, a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that it has filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration for the Dario Blood Glucose Monitoring System.

7 Jan 2014

Medical Condition News

Research opens door to new direction of PAH treatment

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

Cancer statistics 2014 finds steady declines in death rates

Notre Dame, Loyola partner to provide direct support for revolutionary new cancer research

AP-1 proteins modulate fat accumulation in liver, say researchers

Research reveals two new genetic causes of neonatal diabetes

Lower bone strength may predispose children to factures resulting from weakened later in life

Study shows ability to make living human cells from biobanked brain tissue of Alzheimer's patients

Added benefit of dabrafenib not proven

Landes Bioscience releases special issue on sepsis

Erythropoietin may promote cancer cell proliferation and survival

Study sheds light on the biological underpinnings of obesity

Applied BioCode signs License and Supply Agreement with Genetic Analysis for BMB technology

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

Elderly people with high serum vitamin E levels less likely to suffer from memory disorders

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

LabStyle Innovations files 510(k) with FDA for Dario Blood Glucose Monitoring System

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News